Dov Klein - 05 Aug 2021 Form 4 Insider Report for Fortress Biotech, Inc. (FBIO)

Role
Director
Signature
/s/ Samuel Berry, Attorney-in-Fact
Issuer symbol
FBIO
Transactions as of
05 Aug 2021
Net transactions value
-$12,250
Form type
4
Filing time
29 Apr 2022, 16:26:52 UTC
Next filing
04 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FBIO Common Stock, par value $0.001 Other $0 +305 +0.05% $0.000000 655,305 05 Aug 2021 Direct F1, F2
transaction FBIO Common Stock, par value $0.001 Other $0 +480 +0.07% $0.000000 655,785 30 Sep 2021 Direct F1, F2
transaction FBIO Common Stock, par value $0.001 Other $0 +230 +0.04% $0.000000 656,015 16 Nov 2021 Direct F2, F3
transaction FBIO Common Stock, par value $0.001 Sale $12,250 -5,000 -0.76% $2.45 651,015 28 Dec 2021 Direct F2
transaction FBIO Common Stock, par value $0.001 Award $0 +100,000 +15% $0.000000 751,015 01 Jan 2022 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were issued as a dividend pursuant to the Dividend Payment and Exchange Agreement executed by Fortress Biotech, Inc. on March 31, 2021 in favor of the holders of Journey Medical Corporation's 8% Cumulative Convertible Class A Preferred Stock.
F2 The total holdings include 480,000 shares of deferred restricted stock and 40,000 shares underlying deferred restricted stock units.
F3 The shares were issued upon the consummation of Journey Medical Corporation ("Journey's") initial public offering as a partial dividend pursuant to the Dividend Payment and Exchange Agreement executed by Fortress Biotech, Inc. on March 31, 2021 in favor of the holders of Journey's 8% Cumulative Convertible Class A Preferred Stock.
F4 One-third of the shares will vest on each of January 1, 2023, 2024 and 2025, subject to continued service. The reporting person elected to defer 80,000 of these restricted shares pursuant to the issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the reporting person in January of the year following the reporting person's termination of service, or earlier upon his death or change in control of the issuer.
F5 The total holdings include 560,000 shares of deferred restricted stock and 40,000 shares underlying deferred restricted stock units.